NCT05978193View on ClinicalTrials.gov

Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2027

Conditions
Esophageal Squamous Cell CarcinomaEsophageal CancerMetastatic Esophageal Squamous Cell Carcinoma
Interventions
RADIATION

LDRT+CFRT

"LDRT: Primary tumor and all visible metastatic lesions, DT: 2Gy/2fx, d1-2, Q3W × 4 cycles~; CFRT: Primary tumor, DT:40-50Gy/20-25fx, starting from the 5th immunotherapy cycle"

DRUG

Immunotherapy

PD-1 inhibitor 200mg, Q3W, until disease progression or unacceptable toxicity or treatment reaches 2 years

DRUG

Chemotherapy

Paclitaxel+ Cisplatin, Q3W × 4cycles or Paclitaxel+ Carboplatin, Q3W × 4 cycles

Trial Locations (2)

200020

RECRUITING

Shanghai Ruijin Hospital, Shanghai

200030

RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Chest Hospital

OTHER